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Twosimple,fast,andaccurate spectrophotometric methodsforthedeterminationofalendronatesodiumaredescribed. Themeth-
ods are based oncharge-transfer complex formationofthe drug with two π-electron acceptors 7,7,7,8-tetracyanoquinodimethane
(TCNQ) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in acetonitrile and methanol medium. The methods are
followedspectrophotometricallybymeasuringthemaximumabsorbanceat840nmand465nm,respectively. Undertheoptimized
experimental conditions, the calibration curves showed a linear relationship over the concentration ranges of 2–10μgmL −1 and
2–12μgmL −1, respectively. The optimal reactions conditions values such as the reagent concentration, heating time, and stability
of reaction product were determined. No signiﬁcant diﬀerence was obtained between the results of newly proposed methods and
the B.P. Titrimetric procedures. The charge transferapproach using TCNQ and DDQ procedures described in this paper is simple,
fast, accurate, precise, and extraction-free.
1.Introduction
Alendronate sodium is sodium trihydrogen (4-amino-1-hy-
droxybutylidene) biphosphonate trihydrate. It belongs to
the bisphosphonate group and is used for the treatment
of Paget’s disease of bone and osteoporosis, it diminish-
es bone resporption and thus reduces bone turnover [1,
2].
A survey of literature revealed that there are very few
methods available for the determination of alendronate
sodium. These methods include spectrophotometric [3–
6], chromatographic [7–13], capillary electrophoresis [14],
inductively coupled plasma [15], and voltammetric [16].
These previously reported spectrophotometric methods in
t h el i t e r a t u r es u ﬀer from disadvantages like extraction,
long time for the reaction to complete, narrow range of
determination, and lack of sensitivity.
Spectrophotometric techniques continue to be the most
preferred methods for routine analytical work due to their
simplicity and reasonable sensitivity with signiﬁcant eco-
nomical advantages. On the otherhand, it is well known that
p-benzoquinones such as 7,7,7,8-tetracyanoquinodimethane
(TCNQ) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
(DDQ) as π-electron acceptors often form highly colored
electron-donor-acceptor (EDA) or charge transfer (CT)
complexes with various donors which provides the pos-
sibility of determination of drugs by spectrophotometric
methods [17, 18]. In order to develop new simple, fast,
and extraction-free spectrophotometric methods for the
determination of alendronate sodium in pure and pharma-
ceutical dosage forms, we investigated quantitative reactions
of alendronate sodium with organic π -acceptors like TCNQ
and DDQ.
The aimof the present paper isto developthe simple and
accurate spectrophotometric methods for the determination
of alendronate sodium that permits its analysis in dosage
forms without interference from excipients and other cofor-
mulated drugs.2 International Journal of Analytical Chemistry
2.Experimental
2.1. Apparatus. All spectrophotometric measurements were
carried out using a spectrophotometer (U 1100 Hitachi, Ja-
pan) with silica glass cell of 1cm thickness. Oﬃcially, cali-
brated Pyrex glassware was used throughout this study.
2.2. Materials. Alendronate sodium was supplied by Indus
Pharma (Pvt.) Ltd., Karachi, Pakistan. Standard stock solu-
tionofalendronatesodiumwaspreparedbydissolving50mg
pure drug in 20mL methanol and volume was diluted to the
mark in 100mL calibratedﬂask with acetonitrile,formethod
A and with methanol for method B.
2.3. Reagents. All reagents and solvents used were of Ana-
lytical Reagent Grade. 7,7,8,8-tetracyanoquinodimethane
(TCNQ)(Fluka,Austria) 1.0 mg mL−1 solutionwasprepared
in acetonitrile, and 2,3-dichloro-5,6-dicyano-1,4-benzo-
quinone (DDQ) (Fluka, Switzerland) 5.0mg mL−1 solution
was prepared in methanol.
2.4. Assay Procedure
2.4.1. Recommended Assay Procedure
Method A. Aliquots of alendronate sodium (2–10μgmL −1)
were pipetted into a series of 10mL standard measuring
ﬂasks. A one mL volume of 1mgmL−1 solution of 7,7,8,8-
tetracyanoquinodimethane (TCNQ) was added to each ﬂask
and the contents were heated at 70◦Ci nw a t e rb a t hf o rﬁ v e
minutes. Cooled and diluted the content up to the volume
withacetonitrile.Thecoloredproduct,formedandremained
stable for 24hours. The absorbance was measured within the
stabilityperiodafter dilutionat840nm against reagentblank
prepared simultaneously.
Method B. Aliquots of alendronate sodium (2–12 μgm L −1)
were pipetted into a series of 10mL standard measuring
ﬂasks. A 1.2mL volume of 5mgmL−1 solution of 2,3-di-
chloro-5,6-dicyano-1,4-benzoquinone (DDQ) was added to
each ﬂask and the contents were diluted to the volume
with methanol. The colored product formed immediately
and remained stable for two hours. The absorbance was
measured within the stability period after dilution at 465nm
against reagent blank.
2.4.2. Assay Procedure for Tablets. Twenty tablets were accu-
rately weighed and powdered. A portion equivalent to 50mg
of alendronate sodium was stirred with 20mL methanol.
The sample solution was ﬁltered using Whatman ﬁlter
paper number 42. The residue was washed with methanol
or acetonitrile according to the method. The ﬁltrate and
washings were diluted with appropriate solvent to 100mL
using a measuring ﬂask. The aliquot from this ﬁltered
solution was analyzed using the recommended procedures.
2.5. Determination of the Molar Ratio. The Job’s method
of continuous variation was employed. Master equimolar
Table 1:Selected spectral dataforthedeterminationofalendronate
sodium by proposed spectrophotometric methods.
Parameter Values for
method A
Values for
method B
λmax (nm) 840 465
Beer’s law veriﬁcation
range (μgmL −1) 2–10 2–12
Molar absorptivity
(Lmole−1 cm−1) 7.9 × 104 4.6 × 104
Sandell’s sensitivity
(μgml −1 per 0.001A) 4.0 × 10−3 4.9 × 10−3
Regression equation (Y∗)
Slope (b) 0.0254 0.0351
Intercept (a) 0.0238 0.0241
Correlation coeﬃcient (r) 0.9989 0.9997
Limit of detection
(μgmL −1) 0.19 0.30
Limit of quantiﬁcation
(μgmL −1) 0.62 0.99
Y∗: a + bC, where C is the concentration of analyte (μg/mL) and Y is ab-
sorbance unit.
solutions of the drug and color producing reagent were
prepared. The concentration of the drug solution was
5μg/mL. A series of 10mL portions of the master solutions
of the drug with color producing reagent reagent were made
up comprising diﬀerent complementary proportions (0:10,
1:9,..., 9:1, 10:1) in 10mL volumetricﬂasks. The reactions
were allowed toproceed at speciﬁed temperaturesdepending
upon the methods. The absorbances of the solutions were
measured at wavelengths 840nm and 465nm against the
reagent blank.
3.Resultsand Discussion
3.1. Involved Reaction and Absorption Spectra. The reaction
involved in the present study was based on charge transfer
basis. TCNQ is used for quantitative determination of
pharmaceutical drugs in dosagef o r m sb yc h a r g e - t r a n s f e r
complex formation [19, 20]. Interaction of alendronate
sodium with TCNQ in acetonitrile solution was found to
yield a deep color causing characteristic long wavelength
absorption band at 840 nm. The predominant chromagen
with TCNQ is blue-colored radical anion, which probably
resulted through the dissociation of an original donor-
acceptor complex with the drug. This complex is formed by
the lone pair of electron donated by the alendronate sodium
as n-donor and the charge-transfer reagent as an electron
acceptor, which a partial ionic bond (D+ A−) is assumed to
be formed.
D+A
Donor Acceptor
−→ [D −→ A]
Donor-acceptor complex
−→ D+ +A
−
Radical anion
(1)International Journal of Analytical Chemistry 3
Table 2: Determination of alendronate sodium in the presence of possible excipients (5μgmL −1 of alendronate sodium was taken for
interferences studies).
Excipient Amount taken
(gmL−1)
% Recovery ± RSD (N = 5)
method A
% Recovery ± RSD (N = 5)
method B
Microcrystalline cellulose 300 99.6 + 0.25 99.6 + 0.25
Anhydrous lactose 300 99.5 + 0.25 99.5 + 0.25
Magnesium stearate 200 100.1 + 0.30 100.1 + 0.30
Croscarmellose sodium 100 99.8 + 0.40 99.8 + 0.40
Calcium phosphate 50 99.4 + 0.45 99.4 + 0.45
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Figure 1: Absorbance spectra of the colored products produced
from the reaction of alendronate sodium (5μgmL −1) with DDQ
(···) and TCNQ (—).
The dissociation of the complex was promoted by the
high ionizing power of acetonitrile solvent. DDQ is π-
electron acceptor as a result of the strong electron with-
drawing halo and cyano groups conjugated with the π-
system [21, 22]. DDQ reacts instantaneously with basic
nitrogenous compounds to form charge-transfer complexes
of n-π type. The absorption spectrum of DDQ in methanol
shows a characteristic band peaking at 360nm. The addition
of alendronate sodium solution to this solution causes
an immediate change in the absorption spectrum, with
a new characteristic band peaking at 465nm. This band
may be attributed to the formation of DDQ radical anions,
which probably resulted from the dissociation of the donor-
acceptorcomplexinahighlypolarsolventlikemethanol.The
maximum absorption of these charge-transfer complexes is
shown in Figure 1.
3.2. Stoichiometry and Mechanism of the Reaction. The stoi-
chiometry of the reaction between alendronate sodium and
each of TCNQ and DDQ was investigated by Job’s method
of continuous variation as described in experimental section
under the head of “Determination of the Molar Ratio”. The
mole ratio method suggested a donor to acceptor ration 1:1
(Figure 2) conﬁrming the presence of one n-donating center
in the alendronate sodium molecule (Scheme 1).
3.3. Optimization of Reaction Conditions. The spectropho-
tometric properties of the colored species formed with
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Figure 2: Continuous variation plot forthe reaction ofalendronate
sodium and color producing regents.
TCNQ and DDQ as well as diﬀerent parameters aﬀecting the
color development were extensively studied. The optimum
conditions for the assay procedures (Methods A and B) have
been established by studying the reaction as function of the
concentration of the reagent, nature of the solvent, heating
time, and stability of the colored products.
3.3.1. Eﬀect of Color Producing Reagent and Time. For
method A,theeﬀectofvolumeof1mgmL−1 TCNQsolution
was studied over the range of 210 μgmL −1, in a solution
containing 5.0μgmL −1 alendronate sodium. The results
revealed the fact that 1mL of TCNQ solution was required
to achieve the maximum intensity of the color. Therefore
1mL was the optimum value and maintained throughout
the experiment. The reaction gets stabilized within the ﬁve
minutes of heating at 70◦Ci nw a t e rb a t h .
For method B, to study the inﬂuence of the volume of
5mgmL −1 DDQ solution, we pipetted an aliquot of the
drug solution containing 5.0μgmL −1 into a series of 10mL
volumetric ﬂasks, followed by varying volumesof1mgmL−1
DDQ solution (2–12μgmL −1) .T h ec o n t e n t sw e r ed i l u t e d
to the volume with methanol. The highest absorbance was
obtained with volume 1.2mL of 5mgmL−1 DDQ solution.
Further addition of DDQ solution cause-no change in the
absorbance, so 1.2mL was selected the optimum volume
for all determinations. The intensity of the color formed
on mixing the reagent reached maximum with in 40
seconds at room temperature and remained stable for two
hours.4 International Journal of Analytical Chemistry
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Scheme 1: Reaction involved in analysis of alendronate sodium.
Table 3: Determination of alendronate sodium in pharmaceutical formulationsby the proposed and reference [23]m e t h o d s .
Sample Recovery ± S.D.
Oﬃcial method Method A Method B
Fosamax tablets 99.60 ± 0.83 99.75 ± 0.78 99.87 ± 0.69
t 0.24 0.60
F 1.15 1.14
Ostepor tablets 100.02 ± 0.46 99.56 ± 0.53 99.92 ± 0.53
t 1.24 0.54
F 1.58 1.28
Bongard tablets 99.75 ± 0.63 99.90 ± 0.41 100.05 ± 0.61
t 1.42 0.52
F 0.75 1.13
Bonate tablets 100.12 ± 0.52 100.01 ± 0.57 99.89 ± 0.68
t 1.28 0.34
F 1.22 1.12
∗Average of 3 independent analyses.International Journal of Analytical Chemistry 5
3.3.2. Eﬀect of Solvent. The polarity ofthe solvent used in the
reaction between π-acceptors with n-donors can inﬂuence
the formation of charge transfer complexes. Therefore,
investigationswerecarriedouttoestablishthemostfavorable
solvent for the formation of the colored product. The
solvents studied were acetone, dimethyl sulfoxide, N,N-
dimethyl formamide, ethanol, methanol, acetonitrile, and
isopropanol. Alendronate sodium was found to yield a
colored product with TCNQ and DDQ when all these
solvents were used.
However, acetonitrile was the choice solvent since that it
gave maximum intensity and stability of colorfaster than the
others in method A and methanol in method B.
3.4. Analytical Evaluation. TCNQ and DDQ were evaluated
as a chromogenic reagent for spectrophotometric determi-
nation of alendronate sodium. Under the proposed exper-
imental conditions, a linear response between absorbance
and alendronate sodium concentration was veriﬁed. For
method A, Beer’s law was obeyed in a concentration range
from 2 to 10μgmL −1 with correlation coeﬃcient 0.998. The
spectrophotometric method showed a molar absorptivity of
7.9 ×104Lmole−1 cm−1,indicatingagoodsensitivity forthe
samples analyzed.
While for method B, Beer’s law was obeyed in a concen-
tration range from 2 to 12μgmL −1 with correlation coeﬃ-
cient 0.9997 and molar absorptivity of 4.6 × 104Lmole−1
cm−1.
The regression equations for the described procedures
w e r ed e r i v e du s i n gt h el e a s t - s q u a r em e t h o d .T h el i m i to f
detection (10.SDblank/slope of analytical curve) and limit
of quantiﬁcation (10.SDblank/slope of analytical curve) are
shown in Table 1. The analytical parameters and the optical
characteristics for the spectrophotometric determinations of
alendronate sodium by the proposed methods are given in
Table 1.
3.5. Interference Study. To study the potential interference
problems from the commonly used excipients and other ad-
ditives such as microcrystalline cellulose, anhydrous lactose,
magnesium stearate, Croscarmellose, and calcium phos-
phate, recovery studies were carried out. Under the exper-
imental conditions employed, to a known amount of drug
(alendronate sodium 5.0μgmL −1), excipients in diﬀerent
concentrations were added and analyzed. Results of the
recovery analysis are presented in Table 2. Excipients up to
theconcentrationsshown intheTable 2 donot interfere with
the assay. In addition, recoveries in most cases were around
100% and the lower values of the RSD indicate the good
precision of the method.
4.Application
Theapplicabilityoftheproposedmethodsforthedetermina-
tion of alendronate sodium in commercial dosage forms was
examined by analyzing marketed products. The results of the
proposedmethodswere statistically comparedwithreference
method [23] and summarized Table 3.I ti se v i d e n tf r o m
the table that the calculated t and F values [24]a r el e s st h a n
the theoretical ones at 95 % conﬁdence level, indicating no
signiﬁcant diﬀerence between the methods compared. The
proposedmethodsaresensitive,simple,accurate,andextrac-
tion free and are successfully applied for the quality control
ofpurealendronate sodiuminpharmaceuticaldosageforms.
5.Conclusion
The proposed spectrophotometric methods are simple, sen-
s i t i v e ,r a p i d ,a n dl o w - c o s t ,d on o ti n v o l v ea n yp r e t r e a t m e n t
or extraction steps andgives preciseand accurateresults.The
proposed methods were successfully applied to analysis of
alendronate sodium in tablets suggesting its use as a reliable
and advantageous alternative to other previously reported
methods for routine analysis of alendronate sodium in these
samples.
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